Comparison of Clinical Progress of Covid-19 Patients Followed in the Hospital by Vaccination Status

Abstract

Background: Although Covid-19 vaccines cannot prevent infection with SARS-CoV-2, they do allow infected people to have a milder illness. In unvaccinated people, the disease progresses more severely and the disease can be fatal. Both inactivated (Sinovac) and mRNA (Biontech-Pfizer) vaccines are used in Turkey. In this retrospective study, clinical course, radiological involvement and some laboratory parameters that are important for Covid-19 were compared in unvaccinated and vaccinated patients who were infected and followed up in the hospital. Material and methods: Patients between the ages of 17-95 who were hospitalized in the Covid-19 isolation wards between June 2021 and November 2021 were included in the study. Various datas of patients were scanned retrospectively from the hospital registry system. Results: While there was no difference in the mean age, highest fibrinogen, D-dimer, ferritin, creatinine, interleukin-6 (IL6) values and Covid-19 PCR test negative times besides antibody levels, Group 2 (7.8 days) was found to be discharged significantly earlier than Group 1 (12.69 days) (p=0.046). There was a significant difference in low-dose thoracic computed tomography (CT) findings between the two groups (p= 0.023). Discussion: Our study results showed that regardless of the type of vaccine, vaccination against Covid-19 reduces hospitalization rates, length of stay and prevents serious involvement in the lungs.

Keywords

• Covid-19
• Sinovac
• Biontech
• Covid-19 vaccine
• IL-6
• PCR
• SARS-CoV-2
• CT

References

1. World Health Organization. Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: www.who.int/dg/speeches/detail/who- director-general-s-remarks-at-the-media-briefing-on-2019- ncov-on-11-february-2020. Accessed February 12, 2020.
2. V’kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021 Mar;19(3):155-70. doi: 10.1038/s41579-020-00468-6.
3. WHO Coronavirus (COVID-19) Dashboard. Available at: covid19.who.int/. Accessed February, 2022.
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-42. doi: 10.1001/jama.2020.2648.
5. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-43. doi: 10.1001/jamainternmed.2020.0994.
6. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R,ZinkernagelAS,MehraMR,SchuepbachRA,Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020 May 2;395(10234):1417-8. doi: 10.1016/S0140-6736(20)30937-5.
7. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018 Apr;17(4):261-79. doi: 10.1038/nrd.2017.243.
8. Sanders B, Koldijk M, Schuitemaker H. Inactivated viral vaccines. In: Nunnally B, Turula V, Sitrin R, eds. Vaccine Analysis: Strategies, Principles, and Control. Berlin, Heidelberg: Springer; 2015:45-80. doi: 10.1007/978-3-662- 45024-6_2.

9. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-15. doi: 10.1056/NEJMoa2034577.
10. Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, Pullukçu H, Batum Ö, Şimşek Yavuz S, Turhan Ö, Yıldırmak MT, Köksal İ, Taşova Y, Korten V, Yılmaz G, Çelen MK, Altın S, Çelik İ; CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213-22. doi: 10.1016/S0140-6736(21)01429-X.